{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:35:20Z","timestamp":1791286520132,"version":"4.1.0"},"reference-count":71,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:00:00Z","timestamp":1436227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["CCM104886"],"award-info":[{"award-number":["CCM104886"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-na\u00efve individuals can be confronted with the problem of drug resistance through de novo emergence of such variants. Resistant viruses have been reported for every antiretroviral drug tested so far, including the integrase strand transfer inhibitors raltegravir, elvitegravir and dolutegravir. However, de novo resistant variants against dolutegravir have been found in treatment-experienced but not in treatment-na\u00efve individuals, a characteristic that is unique amongst antiretroviral drugs. We review here the issue of drug resistance against integrase strand transfer inhibitors as well as both pre-clinical and clinical studies that have led to the identification of the R263K mutation in integrase as a signature resistance substitution for dolutegravir. We also discuss how the topic of drug resistance against integrase strand transfer inhibitors may have relevance in regard to the nature of the HIV reservoir and possible HIV curative strategies.<\/jats:p>","DOI":"10.3390\/v7072790","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T10:10:02Z","timestamp":1436350202000},"page":"3703-3718","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence"],"prefix":"10.3390","volume":"7","author":[{"given":"Thibault","family":"Mespl\u00e8de","sequence":"first","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wainberg","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Division of Experimental Medicine, Faculty of Medicine, McGill University, Montr\u00e9al, QC H3A 2R7, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1126\/science.7684162","article-title":"Can combination therapy overcome drug resistance?","volume":"260","author":"Cohen","year":"1993","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Development of antiretroviral drug resistance","volume":"365","author":"Wainberg","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/0140-6736(91)90727-7","article-title":"Reversion from zidovudine resistance to sensitivity on cessation of treatment","volume":"338","author":"Land","year":"1991","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1097\/00002030-200111090-00016","article-title":"Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure","volume":"15","author":"Delaugerre","year":"2001","journal-title":"AIDS"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(12)62004-2","article-title":"Dolutegravir for treatment of HIV: Spring forwards?","volume":"381","author":"Waters","year":"2013","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/13543784.2012.658914","article-title":"Elvitegravir: A once-daily inhibitor of HIV-1 integrase","volume":"21","author":"Wills","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/13543784.2012.661713","article-title":"Dolutegravir for the treatment of HIV","volume":"21","author":"Katlama","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1358\/dof.2012.37.10.1855759","article-title":"Dolutegravir HIV integrase inhibitor treatment of HIV infection","volume":"37","author":"Wainberg","year":"2012","journal-title":"Drug Future"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from startmrk","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/COH.0b013e328356db89","article-title":"Resistance to HIV integrase inhibitors","volume":"7","author":"Mesplede","year":"2012","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.coviro.2012.08.007","article-title":"The development of novel HIV integrase inhibitors and the problem of drug resistance","volume":"2","author":"Wainberg","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11908-012-0305-1","article-title":"HIV drug resistance and the advent of integrase inhibitors","volume":"15","author":"Quashie","year":"2012","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890.2014.883169","article-title":"Integrase strand transfer inhibitors in the management of HIV-positive individuals","volume":"46","author":"Mesplede","year":"2014","journal-title":"Ann. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-013-0020-8","article-title":"Integrase strand transfer inhibitors in hiv therapy","volume":"2","author":"Mesplede","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-Week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with hiv-1 infection: A multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":"Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection","volume":"52","author":"Markowitz","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study","volume":"46","author":"Markowitz","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial","volume":"11","author":"Eron","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 Week results from the neat001\/anrs143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/dkp182","article-title":"Rapid selection and archiving of mutation e157q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen","volume":"64","author":"Ghosn","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of hiv infection","volume":"25","author":"Cohen","year":"2011","journal-title":"Aids"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1310\/hct1504-218","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus atazanavir+ritonavir+emtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"15","author":"Kulkarni","year":"2014","journal-title":"HIV Clin. Trials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir df for initial treatment of HIV-1 infection: Analysis of week 144 results","volume":"65","author":"Wohl","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of hiv-1 infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/QAI.0b013e318298469c","article-title":"A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results","volume":"63","author":"Elion","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results","volume":"63","author":"Zolopa","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/QAI.0000000000000089","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF vs. ritonavir-boosted atazanavir plus emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results","volume":"65","author":"Clumeck","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAI.0b013e318286415c","article-title":"A randomized, double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF vs. ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir df for initial treatment of HIV-1 infection: Analysis of week 96 results","volume":"62","author":"Rockstroh","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_33","unstructured":"Kulkarni, R., Abram, M., Rhee, E.G., Fordyce, M.W., Szwarcberg, J., Miller, C.D., and White, K. (2014, January 3\u20136). Week 144 resistance analyses of the phase 3 evg\/cobi\/ftc\/tdf studies. Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. Poster number 587."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (s\/gsk1349572) in combination therapy in antiretroviral-naive adults with HIV: Planned interim 48 week results from spring-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"Maggiolo","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (flamingo): 48 Week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (spring-2 study): 96 Week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with hiv-1 infection: 48 Week results from the randomised, double-blind, non-inferiority spring-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant hiv type 1 infection: 24-Week results of the viking study","volume":"207","author":"Eron","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Akil, B., Blick, G., Hagins, D.P., Ramgopal, M.N., Richmond, G.J., Samuel, R.M., Givens, N., Vavro, C., Song, I.H., and Wynne, B. (2014). Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-Week results from viking-4, a randomized study. Antivir. Ther., 20.","DOI":"10.3851\/IMP2878"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-Week results of the phase III viking-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority sailing study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the r263k mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mesplede","year":"2013","journal-title":"Retrovirology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-4690-11-7","article-title":"The m50i polymorphic substitution in association with the r263k mutation in HIV-1 subtype b integrase increases drug resistance but does not restore viral replicative fitness","volume":"11","author":"Wares","year":"2014","journal-title":"Retrovirology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/jac\/dku199","article-title":"Addition of e138k to r263k in hiv integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity","volume":"69","author":"Mesplede","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1741-7015-11-249","article-title":"What if HIV were unable to develop resistance against a new therapeutic agent?","volume":"11","author":"Wainberg","year":"2013","journal-title":"BMC Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/QAD.0000000000000199","article-title":"Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors","volume":"28","author":"Oliveira","year":"2014","journal-title":"AIDS"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1128\/AAC.05181-14","article-title":"Combination of the r263k and m184i\/v resistance substitutions against dolutegravir and lamivudine decreases hiv replicative capacity","volume":"59","author":"Singhroy","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QAD.0000000000000606","article-title":"Dolutegravir inhibits HIV-1 env evolution in primary human cells","volume":"29","author":"Mesplede","year":"2015","journal-title":"AIDS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/cid\/ciu477","article-title":"Ing116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects","volume":"59","author":"Letendre","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of s\/gsk1349572, a next-generation hiv integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults","volume":"25","author":"Min","year":"2011","journal-title":"AIDS"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/AAC.00292-13","article-title":"Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans","volume":"57","author":"Castellino","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3851\/IMP2665","article-title":"Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women","volume":"18","author":"Adams","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of s\/gsk1349572, a next-generation hiv integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1128\/AAC.00507-10","article-title":"Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1","volume":"54","author":"Croteau","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/14656566.2015.1044436","article-title":"HIV integrase inhibitors: A new era in the treatment of HIV","volume":"16","author":"Blanco","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Osman, N., Mespl\u00e8de, T., Quashie, P.K., Oliveira, M., Zanichelli, V., and Wainberg, M.A. (2015). Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. J. Antimicrob. Chemother., in press.","DOI":"10.1093\/jac\/dkv176"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gandhi, R.T., Zheng, L., Bosch, R.J., Chan, E.S., Margolis, D.M., Read, S., Kallungal, B., Palmer, S., Medvik, K., and Lederman, M.M. (2010). The effect of raltegravir intensification on low-level residual viremia in hiv-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med., 7.","DOI":"10.1371\/journal.pmed.1000321"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/QAI.0b013e31823fd1f2","article-title":"No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy","volume":"59","author":"Gandhi","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/infdis\/jit453","article-title":"Increase in 2-ltr circles and decrease in d-dimer after raltegravir intensification in treated HIV-infected patients: A randomized, placebo-controlled trial","volume":"208","author":"Hatano","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1093\/jac\/dkt183","article-title":"Early but limited effects of raltegravir intensification on CD4 t cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy","volume":"68","author":"Negredo","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3851\/IMP1917","article-title":"Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: A randomized 48-week study","volume":"17","author":"Llibre","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0b013e32834e8955","article-title":"Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: A randomized controlled trial","volume":"26","author":"Chege","year":"2012","journal-title":"AIDS"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jiq138","article-title":"A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response","volume":"203","author":"Hatano","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(15)70021-6","article-title":"Intensive five-drug antiretroviral therapy regimen versus standard tripe-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS147): A randomised, open-label, phase 3 trial","volume":"15","author":"Nembot","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/QAI.0000000000000111","article-title":"A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals","volume":"66","author":"Markowitz","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S2055-6640(20)30482-9","article-title":"Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification","volume":"1","author":"Ananworanich","year":"2015","journal-title":"J. Virus Erad."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e1002314","DOI":"10.1371\/journal.ppat.1002314","article-title":"Deep molecular characterization of HIV-1 dynamics under suppressive HAART","volume":"7","author":"Buzon","year":"2011","journal-title":"PLoS Pathog."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/7\/2790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:48:50Z","timestamp":1760215730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/7\/2790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"alternative-id":["v7072790"],"URL":"https:\/\/doi.org\/10.3390\/v7072790","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,7]]}}}